The market for EGFR lung cancer drugs has been put on hold. Sales of Tagrisso, a third-generation drug, have declined since its benefit. As new products emerge one after another, the market is expected to change within this year.

According to IQVIA, a pharmaceutical research institute, the size of Korea's market for EGFR tyrosine kinase inhibitors (TKI) in the first quarter of last year was ₩35.5 billion, down 2.9% from ₩36.5 billion a year earlier. South Korea's EGFR-TKI market increased to ₩38.9 billion in sales in third quarter of last year as it continued to grow since first quarter of 2017, but fell for second consecutive quarter.